Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) lower low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. However, some patients receiving PCSK9i therapy might require additional lipid-lowering therapy (LLT) to reach LDL-C goals. Bempedoic acid is an oral, once-daily, ATP-citrate lyase inhibitor that significantly lowers LDL-C in patients with hypercholesterolemia when given alone or as add-on therapy to statins and/or ezetimibe.

Sorting the assemblies of unsymmetrically covalently functionalized mn-anderson polyoxometalate clusters with mass spectrometry.

The unsymmetrical Mn-Anderson polyoxometalate cluster, [N(C4H9)4]3[MnMo6O18(C4H6O3NO2)(C4H6O3NH2)] (1; N(C4H9)4(+) = TBA(+)), has been prepared and characterized by X-ray crystallography and electrospray ionization mass spectrometry (ESI-MS). Covalent functionalization of compound 1 leads to the controlled assemblies of unsymmetrical alkoxopolyoxometalate clusters of compounds 2-5, which can be directly observed in solution as revealed by ESI-MS studies.